Literature DB >> 14680778

ERG rod a-wave in Oguchi disease.

Tomoaki Usui1, Naoyuki Tanimoto, Satoshi Ueki, Mineo Takagi, Shigeru Hasegawa, Haruki Abe, Keigo Sekiya, Mitsuru Nakazawa.   

Abstract

We analyzed the change in the ERG rod a-wave waveform during the course of dark adaptation in two patients with Oguchi disease. Two Japanese patients showed a homozygous arrestin 1147delA mutation. Scotopic flash ERGs were recorded after different periods of dark adaptation. ERG rod a-waves were obtained after subtraction of the cone ERG contribution. The rod a-waves were fitted with a model of the rod receptor signal. The parameters, Rm(p3) (maximum a-wave amplitude) and S (sensitivity) were calculated. Longer periods in the dark produced larger rod a-wave but only to the first flash presented. The amplitude of the response to subsequent flashes was essentially independent of the period of dark adaptation. Rm(p3) increased with advance of dark adaptation. However, S was nearly constant. Our results suggest that the cause of delayed dark adaptation is not to be sought in the activation of phototransduction process or the regeneration of rhodopsin per se but rather in the deactivation process of the phototransduction cascade.

Entities:  

Mesh:

Year:  2004        PMID: 14680778     DOI: 10.1016/j.visres.2003.06.003

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  2 in total

1.  Empirical mode decomposition and neural network for the classification of electroretinographic data.

Authors:  Abdollah Bagheri; Dominique Persano Adorno; Piervincenzo Rizzo; Rosita Barraco; Leonardo Bellomonte
Journal:  Med Biol Eng Comput       Date:  2014-06-13       Impact factor: 2.602

2.  A compound heterozygous mutation in the S-Antigen Visual Arrestin SAG gene in a Chinese patient with Oguchi type one: a case report.

Authors:  Zhen Deng; Fangli Fan; Danyan Tang; Yifeng Wu; Yujie Shu; Kunlin Wu
Journal:  BMC Ophthalmol       Date:  2022-03-04       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.